GlassScriptPhysician profile
Raul Gaona
NPI 1649259920
$3,306.65
in general payments reported to CMS, 2019-2025
26 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,826 · 2020: $123 · 2021: $173 · 2022: $327 · 2023: $451 · 2024: $56.15 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $511.49 | 2019-2022 | |
| Novo Nordisk INC | $485.83 | 2019-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $480.16 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $440.80 | 2019-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $343.05 | 2019 | |
| Bard Peripheral Vascular, INC. | $136.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.81 | 2019 | |
| Novartis Pharmaceuticals Corporation | $123.32 | 2019 | |
| Cardiva Medical, INC. | $117.02 | 2023 | Cardiva Vascade 6/7f Vcs |
| Horizon Therapeutics Plc | $63.52 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $63.40 | 2019 | |
| Abbott Laboratories | $62.71 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $58.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $48.01 | 2019-2021 | |
| Amarin Pharma, INC. | $39.13 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.10 | 2019 | |
| Glaxosmithkline, LLC. | $27.53 | 2019 | |
| Astellas Pharma US INC | $26.89 | 2019 | |
| Si-Bone, INC. | $22.33 | 2021 | |
| Mannkind Corporation | $20.99 | 2019 | |
| Genentech USA, INC. | $17.06 | 2019 | |
| Medtronic USA, INC. | $15.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.50 | 2019 | |
| Scilex Pharmaceuticals INC. | $11.66 | 2019 | |
| Siemens Medical Solutions USA, INC. | $11.37 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Gaona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.